Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients

Haifeng Deng1,2,3, Hongbing Shi1,2,3, Lujun Chen1,2,3, You Zhou1,2,3 and Jingting Jiang1,2,3*

Abstract

Background: Nectin-4, also known as PVRL4 (poliovirus-receptor-like 4), is specifically expressed in the embryo and placenta. Recent studies have reported that the Nectin-4 is over-expressed in multiple human cancers, and such abnormal expression is associated with cancer progression and poor prognosis of the patients. In the present study, we aimed to characterize the expression pattern of Nectin-4 in human esophageal cancer (EC) tissues, and to investigate its clinical implications, prognostic value and regulatory effects on cellular functions of EC cells.

Methods: In the present study, we first examined Nectin-4 expression in human EC tissues by using immunohistochemistry (IHC) assay and analyzed the clinical associations. Then the cellular studies in vitro and the nude mice tumor model in vivo were used to examine the regulatory role of Nectin-4 in the progression of EC.

Results: Our results demonstrated that over-expression of Nectin-4 in human EC tissues was significantly associated with tumor size, depth of tumor invasion, and poor prognosis of the patients. The intervention of Nectin-4 expression in EC cell lines showed that the increased Nectin-4 expression could significantly promote the cell viability, migration, invasion and tumor formation.

Conclusions: Our present data unveiled that Nectin-4 played an important role in tumor biology and could serve as a useful prognostic predictor of human EC.

Keywords: Nectin-4, Esophageal cancer, Cancer progression, Prognosis
and breast cancers, and the expression level of Nectin-4 in cancer tissues is significantly associated with cancer progression and poor prognosis of the patients [7–13]. Moreover, the abnormal expression of Nectin-4 in cancer cells could also regulate the cellular functions and angiogenesis [9]. Moreover, in addition to its membranous form, the soluble Nectin-4 can also be detected in serum from cancer patients, and therefore the serum level of soluble Nectin-4 can serve as important prognostic risk factor for the patients [8, 12].

In our present study, we aimed to characterize the expression pattern of Nectin-4 in human EC tissues, and to investigate its clinical implications and prognostic value. Moreover, we also performed in vitro and in vivo studies to further examine the effect of intervention of Nectin-4 expression on the cellular functions of EC cells. Our results demonstrated that over-expression of Nectin-4 in human EC tissues was significantly associated with tumor size, depth of tumor invasion, and poor prognosis of the EC patients. The intervention of Nectin-4 expression in EC cell lines could regulate the cell viability as well as the abilities of migration, invasion and tumor formation. Taken together, our present data unveiled that Nectin-4 played a crucial role in tumor biology, and it could serve as a useful prognostic predictor of human EC.

Materials and methods

Patients and tissue samples

The human EC tissue array (catalog: Heso-Squ172Sur-01) was purchased from Shanghai Outdo Biotech Co., Ltd. (Shanghai, P. R. China). A total of 94 patients who underwent surgery between July 2006 and October 2008 were enrolled in this study. Among these patients, 78 cases of adjacent normal tissues were also included in the tissue array. All these cancer tissues and adjacent normal tissues were confirmed using hematoxylin and eosin (H&E) staining after surgical resection. Incomplete tissue samples and several missing tissue samples were excluded during the heat-induced antigen retrieval, and finally a total of 82 cases were included in the present statistical analysis. Table 1 shows the detailed clinical parameters of the participants. All patients gave informed consent for participation, and the protocol for the present study was approved by the ethics committee of the Third Affiliated Hospital of Soochow University.

Immunohistochemical staining and evaluation

The immunostaining of Nectin-4 in EC tissue array was performed according to our published protocol [14, 15]. Briefly, the antigen retrieval was carried out by heating the tissue sections at 100 °C for 30 min in EDTA solution (pH 9.0). Goat anti-human Nectin-4 antibody (AF2659, R&D Systems) was used at the concentration of 10 μg/mL. The Polink-2 plus® polymer HRP detection system for goat primary antibody (Zhongshan Golden Bridge Biotechnology, Beijing, China) was used according to the manufacturer’s instructions. Diaminobenzene was used as the chromogen, and hematoxylin was employed as the nuclear counterstain. The evaluation of Nectin-4 staining was performed according to the H-score method as described in our published reports [14–17].

Cell culture

Human EC cell lines Eca-109 and TE-1 were obtained from Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences. The cells were maintained in RPMI-1640 or DMEM supplemented with 10% FBS in the presence of benzylpenicillin (100 U/mL), streptomycin (100 μg/mL) and 2 mM l-glutamine, and were cultured under standard culture conditions (5% CO₂, 37 °C).

Nectin-4 over-expression, RNAi lentivirus generation, infection and cell sorting

The full-length of Nectin-4 (NM_030916.2; GenBank) fragment was synthesized by Sangon Biotech Shanghai Co., Ltd. (Shanghai, China) and cloned to pLV-IRES-ZsGreen-T2A-puro vector (Promega Biotech Co., Ltd., Madison, WI, USA). The small hairpin RNA (shRNA) against the human Nectin-4 gene was obtained from

| Table 1 Correlation between esophageal cancer tissues and patients’ clinical parameters |
|-------------------------------------|-----------------|-----------------|-----------------|------|
| Clinical parameters               | Cases | Nectin-4 expression level | P       |       |
|                                   |       | H-score<70 | H-score≥70 |       |
| Age (years)                       |       |           |           | 0.004 | 0.951 |
| <60                                | 23    | 6         | 17        |       |
| ≥60                                | 59    | 15        | 44        |       |
| Tumor size (cm)                   |       |           |           | 6.385 | 0.012 |
| <4.5                               | 43    | 16        | 27        |       |
| ≥4.5                               | 39    | 5         | 34        |       |
| Gender                             |       |           |           | 0.437 | 0.509 |
| Male                               | 62    | 17        | 45        |       |
| Female                             | 20    | 4         | 16        |       |
| Lymph node metastasis             |       |           |           | 0.067 | 0.796 |
| No                                 | 42    | 10        | 32        |       |
| Yes                                | 38    | 10        | 28        |       |
| TNM stage                          |       |           |           | 0.530 | 0.467 |
| I–II                               | 40    | 8         | 32        |       |
| III–IV                             | 37    | 10        | 27        |       |
| Tumor stage                        |       |           |           | 5.822 | 0.016 |
| T1 + T2                            | 15    | 7         | 8         |       |
| T3 + T4                            | 63    | 11        | 52        |       |

Italic signifies P<0.05
Shanghai GeneChem Co. Ltd (Shanghai, China), and cloned into a lentiviral gene transfer vector pLV-U6-GFP. The shRNA target sequence against Nectin-4 was 5′-CACTCCAAATACGGGCTTCAT-3′. The EC cell lines Eca-109 and TE-1 were transfected with LV-Nectin-4-shRNA, LV-NC, LV-Nectin-4-OE, and LV-Vector-Ctrl, and then selected using puromycin (2 µg/mL; Sigma-Aldrich; Merck Millipore) for more than 2 weeks.

**Real-time RT-PCR**

Total RNA was extracted from EC cells, and the RNA quality was determined according to the methods as described in our previous studies [18]. The PCR reactions were performed on an ABI 7600 system (Applied Biosystems, USA) according to the manufacturer’s instructions. Human GAPDH was selected as a housekeeping gene. Primers were synthesized as follows, GAPDH forward primer: 5′-TGACTTCAACAGGCACACCCA-3′, GAPDH reverse primer: 5′-CACCTGTTGCTGACTGACAAA-3′; Nectin-4 forward primer: 5′-CTGAGCAGGTTCAGGTTT-3′, Nectin-4 reverse primer: 5′-AGAGTTCTTGGCTCTCGCAG-3′. The relative expression of Nectin-4 was calculated by the 2−ΔΔCT method.

**Western blot analysis**

The expression of Nectin-4 at the protein level in different cellular models was determined by Western blotting analysis according to the protocol described in our published reports [14, 15].

**Cell viability assay**

The effects of Nectin-4 intervention on biological functions of EC cell lines were assessed according to our previously published protocols [14, 15]. Cell viability was assessed using Cell Counting Kit-8 (CCK-8, Beyotime, Shanghai, China) according to the manufacturer’s instructions. Briefly, 5 × 10^5 Eca-109 or TE-1 cells from LV-Nectin-4-shRNA, LV-NC, LV-Nectin-4-OE and LV-Vector-Ctrl were seeded into 96-well plates and incubated for 24, 48 and 72 h. CCK-8 reagent was added to each well at 3 h before the endpoint of incubation, and the absorbance of each well was determined at a wavelength of 450 nm by a microplate reader. An increase or decrease in the absorbance of experimental wells relative to the initial values indicates cell growth or death, respectively. Each experiment was repeated for at least three times.

**Wound healing assay**

Eca-109 or TE-1 cells from LV-Nectin-4-shRNA, LV-NC, LV-Nectin-4-OE and LV-Vector-Ctrl groups were cultured in 6-well plates. A small wound area was created using a 200-µL pipette tip when cells reached a 90% confluence. Cells were washed twice with PBS and then incubated in serum-free RPMI-1640 or DMEM medium at 37 °C for 48 h in a 5% CO2 incubator. Photographs were acquired at two different time points (0 and 24 h). Wound width was measured using a BX50 microscope (Olympus®) with a calibrated eyepiece grid. Data from three independent experiments were averaged and expressed as a percentage of the original width.

**Invasion assay**

The invasion assay was used to evaluate the effect of intervention of Nectin-4 expression on the invasion ability of human esophageal cancer cells as previously described [12, 13]. Briefly, cells from the different groups were placed in the upper chamber of Matrigel-coated invasion chamber (Corning, NY, USA) and serum-starved for 24 h, and then the medium containing 10% FBS was placed in the lower chamber as a chemo-attractant. After 48 h of incubation, those cells that migrated into the lower chamber were collected and re-suspended, and non-migrating cells were removed from the top of the Matrigel with a cotton-tipped swab. Migrated cells were fixed and stained with 0.1% crystal violet and later photographed under a microscope (Olympus, Tokyo, Japan). Finally, the migrated cells were counted from five randomly selected fields.

**Cell cycle assay**

The Eca-109 or TE-1 cells from LV-Nectin-4-shRNA, LV-NC, LV-Nectin-4-OE and LV-Vector-Ctrl groups were cultured in 6-well plates and cultured for 48 h. The cells were then washed with ice-cold PBS and fixed in a 70% (v/v) ice-cold ethanol solution at 4 °C overnight. Subsequently, these cells were analyzed by flow cytometry according to the instructions of cell cycle analysis kit (Sigma, MO, USA). The cell cycle information was analyzed using ModFit LT 4.0 software.

**Subcutaneous transplantation model study**

The subcutaneous transplantation model study was performed according to our previously published protocol [19]. Briefly, eight groups of female Balb/c nude mice (4–6 weeks old, five mice for each group) were bred under a specific-pathogen-free (SPF) condition with constant humidity and temperature (25–28 °C). Animal protocols were approved by the Animal Care and Use Committee and carried out in compliance with the Guidelines on Animal Welfare of the China National Committee for Animal Experiments. Eca-109 cells (1 × 10^7) or TE-1 cells (1 × 10^7) from LV-Nectin-4-shRNA, LV-NC, LV-Nectin-4-OE and LV-Vector-Ctrl groups were suspended in 0.15 mL PBS, and cell suspension was subcutaneously injected into the left sides of mice.
injected into the right back region of nude mice. The tumor size was measured every 2 days with caliper, and the volume was calculated using the formula as follows: \( \text{Length} \times \text{Width}^2 \times \pi/6 \). Growth curves were constructed, and the data were presented as mean \( \pm \) SEM. Finally, the tumors were harvested from mice at 28 days post injection. The protocol for the tumor model by using nude mice in the present study was approved by the ethics committee of the Third Affiliated Hospital of Soochow University.

Statistical analyses
Statistical analysis was completed using the paired Student’s \( t \)-test, the Wilcoxon signed rank test, the two way ANOVA analysis, the Chi square test or the Log-rank survival analysis where appropriate for final analysis of the data. All the statistical analyses were performed using the GraphPad Prism 5.0 software package (GraphPad Software, Inc., San Diego, USA). A \( P \)-value of < 0.05 was considered as statistically significant.

Results
Survey of Nectin-4 expression at mRNA level in human EC tissues based on TCGA data
According to the data from https://www.proteinatlas.org, we characterized Nectin-4 expression in different normal human tissues, and the results revealed that Nectin-4 expression could found in normal esophagus tissues at both mRNA (Fig. 1a) and protein (Fig. 1b) levels. Moreover, based on the TCGA data from http://gepia.cancer-pku.cn/, we studied the mRNA expression levels of Nectin family members including Nectin-1, -2, -3 and -4 in human EC tissues, Fig. 2c shows that the mRNA expression level of Nectin-3 was significantly higher in cancer tissues compared with that in adjacent normal tissues (\( P < 0.05 \)). Figure 2d illustrates
that the mRNA expression level of Nectin-4 was significantly higher in adjacent normal tissues compared with cancer tissues ($P < 0.05$), while there were no any significant differences in terms of the expressions of Nectin-1 and Nectin-2 between cancer tissues and adjacent normal tissues (Fig. 1a, b). Then we further examined the correlations between the expressions of Nectin-4 in EC tissues and other members namely Nectin-1, -2 and -3. Our results demonstrated that the mRNA expression level of Nectin-4 was significantly higher in cancer tissues compared with adjacent normal tissues ($P < 0.05$), and the mRNA expression level of Nectin-4 was significantly higher in adjacent normal tissues compared with cancer tissues ($P < 0.05$). We found that the expression of Nectin-4 at the mRNA level in EC tissues was positively and significantly correlated with that of Nectin-1 ($P < 0.0001$), while it was negatively and significantly correlated with that of Nectin-2 ($P < 0.0001$) and Nectin-3 ($P < 0.0001$). We didn’t find any significant correlations between patients’ postoperative survival and Nectin-1 or Nectin-2. The overall survival rate of the patients with higher expression of Nectin-3 at the mRNA level was significantly greater compared with those showing lower Nectin-3 expression ($P = 0.006$). The patients with lower expression of Nectin-4 at the mRNA level exhibited better overall survival rate compared with those showing higher Nectin-4 expression, although the difference was not significant ($P = 0.266$).
Furthermore, we also examined the prognostic value of Nectin family members in human EC tissues based on TCGA data. We didn't find any significant correlations between patients' postoperative survival and Nectin-1 or Nectin-2 (Fig. 2h, i). Figure 2j reveals that the overall survival rate of the patients with higher expression of Nectin-3 at the mRNA level was significantly greater compared with those showing lower Nectin-3 expression ($P = 0.006$). Moreover, the patients with lower expression of Nectin-4 at the mRNA level exhibited better overall survival rate compared with those showing higher Nectin-4 expression, although the difference was not significant (Fig. 2k, $P = 0.266$).

**Nectin-4 expression in human EC tissues and its clinical implications**

In order to further investigate the clinical significance of Nectin-4 expression in human EC, we carried out the immunohistochemistry to study the expression of Nectin-4 in EC tissues. Figure 3a shows that positive staining of Nectin-4 could be found in the cytoplasm and on the membrane of the cancer cells, while weak or negative staining of Nectin-4 could be found in normal esophageal tissues (Fig. 3b). Figure 3c reveals that the staining intensity of Nectin-4 in EC tissues was significantly higher than that in adjacent normal tissues ($P < 0.0001$). Moreover, the survival analysis showed that the overall survival rate of the patients with higher Nectin-4 expression was significantly poorer compared with those showing lower Nectin-4 expression (HR = 1.704, 95% CI 1.027–2.825, $P = 0.039$).
significantly poorer compared with those showing lower Nectin-4 expression \((HR=1.704, 95\% \ CI \ 1.027–2.825, P=0.039)\) (Fig. 3d).

Besides, we also analyzed the associations between the expression of Nectin-4 in EC tissues and patient's clinical parameters. Table 1 shows that the staining intensity of Nectin-4 was positively and significantly associated with tumor size \((P=0.012)\) and tumor stage \((P=0.016)\). According to the COX model analysis, the Nectin-4 expression level could serve as an independent prognostic predictor for EC patients (Table 2, \(HR=1.795, 95\% \ CI \ 1.042–3.092, P=0.035)\), suggesting that abnormal

### Table 2 Cox model analysis for the correlation between Nectin-4 expression level and patients' clinical parameters

| Clinical parameters                      | Uni-vari\(\)te | \(P\) | Multi-vari\(\)te | \(P\) |
|-----------------------------------------|----------------|------|------------------|------|
| Gender (M/F)                            | 2.618 (1.285–5.337) | 0.008 | 1.827 (0.765–4.364) | 0.175 |
| Age (years) \((\geq 60/< 60)\)           | 1.093 (0.630–1.894) | 0.752 | 1.543 (0.828–2.878) | 0.172 |
| Tumor size \((\geq 4.5 \text{ cm}/< 4.5 \text{ cm})\) | 1.674 (1.014–2.763) | 0.044 | 1.363 (0.792–2.346) | 0.264 |
| Pathological stage \((\text{III–IV}/\text{I–II})\) | 0.805 (0.436–1.485) | 0.487 | 0.723 (0.377–1.385) | 0.328 |
| Tumor stage \((\text{T3–T4}/\text{T1–T2})\) | 2.950 (0.923–7.127) | 0.008 | 1.613 (0.898–5.021) | 0.087 |
| Lymph node metastasis \((\text{yes}/\text{no})\) | 2.518 (1.290–3.609) | 0.003 | 1.689 (0.928–3.074) | 0.086 |
| Nectin-4 expression \((\text{high}/\text{low})\) | 1.704 (1.027–2.825) | 0.039 | 1.795 (1.042–3.092) | 0.035 |

![Fig. 4](image-url)  
**Fig. 4** Knockdown expression and over-expression of Nectin-4 in human EC cell lines Eca-109 and TE-1. **a** The knockdown expression of Nectin-4 at mRNA level by using RNAi approach in human EC lines was confirmed by real-time RT-PCR, and the Nectin-4 mRNA expression level in LV-Nectin-4-shRNA group cells was significantly lower than that in LV-NC group cells (both in Eca-109 and in TE-1, \(P<0.0001)\). **b** The decreased Nectin-4 protein expression after knockdown in human EC cell lines Eca-109 and TE-1, were confirmed by using western blot method. **c** The Nectin-4 protein expression level in LV-Nectin-4-shRNA group cells was significantly lower than that in LV-NC group cells (in Eca-109, \(P<0.01)\, and in TE-1, \(P<0.001)\). **d** The over-expression of Nectin-4 at mRNA level in human EC lines was confirmed by real-time RT-PCR, which showed that the increased Nectin-4 mRNA expression level in LV-Nectin-4-OE group cells compared with LV-Vector-Ctrl group cells (both in Eca-109 and in TE-1, \(P<0.0001)\). **e** The increased Nectin-4 protein expression in human EC cell lines Eca-109 and TE-1 were confirmed by using western blot method. **f** The Nectin-4 protein expression level in LV-Nectin-4-OE group cells was significantly higher than that in LV-Vector-Ctrl group cells (in Eca-109, \(P<0.01)\, and in TE-1, \(P<0.001)\).
Expression of Nectin-4 was involved in the progression of EC.

**Intervention of Nectin-4 expression in human EC cells**

In order to further investigate whether the intervention of Nectin-4 expression in human EC cells had effects on cellular functions, we also carried out the cellular study on the knock-down expression or over-expression of Nectin-4 in EC cells. Figure 4 shows that Nectin-4-knockdown expression or Nectin-4-over-expressing cell lines were successfully established using lentiviral transfection, and both real-time RT-PCR and Western blotting analyses were used to confirm the intervention of Nectin-4 expression in human EC cells at the mRNA and protein levels, respectively.

**Effect of intervention of Nectin-4 expression on cellular functions of human EC cell lines**

We then examined the effects of the intervention of Nectin-4 expression on cell proliferation in vitro by using CCK-8 assay in human EC cell lines. As shown in Fig. 5a, in Eca-109 cells, at 48 as well as 72 h after seeding, the proliferation rate of LV-Nectin-4-shRNA group cells was significantly lower than that of LV-NC group cells (both $P<0.01$). Figure 5b shows that, in Eca-109 cells, at 48 as well as 72 h after seeding, the proliferation rate of LV-Nectin-4-OE group cells was significantly higher than that of LV-Vector-Ctrl group cells (both $P<0.01$). As shown in Fig. 5c, in TE-1 cells, at 24, 48 as well as 72 h after seeding, the proliferation rate of LV-Nectin-4-shRNA group cells was significantly lower than that of the LV-NC group (all $P<0.01$). Figure 5d shows that, in TE-1 cells, at 48 and 72 h after seeding, the proliferation rate of LV-Nectin-4-OE group cells was significantly higher compared with the LV-Vector-Ctrl group (both $P<0.01$).

---

**Fig. 5** Effect of intervention of Nectin-4 expression on cell proliferation of human EC cell lines. We examined the intervention of Nectin-4 expression on cell proliferation in vitro using CCK-8 assay in human EC cell lines. a In Eca-109 cells, at 48 and 72 h after seeding, the cell proliferation rate of LV-Nectin-4-shRNA group was significantly lower compared with the LV-NC group (both $P<0.01$). b In Eca-109 cells, at 48 and 72 h after seeding, the cell proliferation rate of LV-Nectin-4-OE group was significantly higher compared with the LV-Vector-Ctrl group (both $P<0.01$). c In TE-1 cells, at 24, 48 and 72 h after seeding, the cell proliferation rate of LV-Nectin-4-shRNA group was significantly lower compared with the LV-NC group (all $P<0.01$). d In TE-1 cells, at 48 and 72 h after seeding, the cell proliferation rate of LV-Nectin-4-OE group was significantly higher compared with the LV-Vector-Ctrl group (both $P<0.01$).
of LV-NC group cells ($P<0.01$ respectively). Figure 5d shows that in TE-1 cells, at 48 as well as 72 h after seeding, the proliferation rate of LV-Nectin-4-OE group cells was significantly higher than that of LV-Vector-Ctrl group cells (both $P<0.01$). Moreover, the wound-healing assay was performed to evaluate the effect of the intervention of Nectin-4 expression on the migration ability of human EC cell lines. Knockdown of Nectin-4 expression significantly decreased the cell migration ability of Eca-109 and TE-1 cells, showing that the cell-free area of the LV-Nectin-4-shRNA group was significantly wider than that of the LV-NC group at 24 h (Fig. 6a, in Eca-109, $P<0.05$, and in TE-1, $P<0.01$). Over-expression of Nectin-4 expression significantly increased the cell migration ability of Eca-109 and TE-1 cells, showing that the cell-free area of LV-Nectin-4-OE group was significantly narrower than that of the LV-Vector-Ctrl group at 24 h (Fig. 6b, both $P<0.01$). Furthermore, the transwell invasion assay was performed to evaluate the effect of the intervention of Nectin-4 expression on the invasion ability of human EC cell lines. Knockdown of Nectin-4 expression significantly decreased the number of invaded cells stained with Cristal Violet in the LV-Nectin-4-shRNA group cells compared with the LV-NC group cells (Fig. 7a, in Eca-109, $P<0.01$, and in TE-1, $P<0.001$). Nectin-4 over-expression significantly increased the number of invaded cells stained with Cristal Violet in the LV-Nectin-4-OE group cells compared with the LV-Vector-Ctrl group cells (Fig. 7b, both $P<0.001$).

**Effect of Nectin-4 intervention on tumor growth in the subcutaneous transplantation mouse model**

In order to study the effect of abnormal Nectin-4 expression on the regulation of tumor growth in vivo, we then established the subcutaneous transplantation mouse model. Eca-109 or TE-1 cells of LV-Nectin-4-shRNA, LV-NC, LV-Nectin-4-OE and LV-Vector-Ctrl groups were subcutaneously injected into nude mice. In the tumor model established using Eca-109 cells, the tumor growth curves showed that knockdown expression of Nectin-4 significantly inhibited the tumor growth (Fig. 8a, $P=0.0001$), while the tumor growth of Nectin-4 over-expression group also tended to be faster than that of control group (Fig. 8a, $P=0.0831$). After 28 days, the tumor weight of the LV-Nectin-4-shRNA group was lighter compared with the LV-NC group (Fig. 8c, $P<0.05$), and the tumor weight of the LV-Nectin-4-OE group trended to be heavier compared with the LV-Vector-Ctrl group.
group (Fig. 8c, \(P < 0.001\)). In the tumor model established using TE-1 cells, the tumor growth curves showed that knockdown expression of Nectin-4 significantly inhibited the tumor growth (Fig. 8d, \(P < 0.001\)), while the tumor growth of Nectin-4 over-expression group also trended to be faster than that of control group (Fig. 8d, \(P = 0.1816\)). After 28 days, the tumor weight of the LV-Nectin-4-shRNA group was lighter compared with the LV-NC group (Fig. 8f, \(P < 0.0001\)), and the tumor weight of the LV-Nectin-4-OE group trended to be heavier compared with the LV-Vector-Ctrl group (Fig. 8f, \(P = 0.1314\)).

**Discussion**

Esophageal cancer is one of the most common malignant tumors of the digestive system, especially in China [20–22]. Although some improvements have been made in the diagnosis and treatment of EC, the 5-year survival rate of the patients with advanced EC still remains less than 15% due to lymph node invasion and distant metastasis [20, 21]. Therefore, it is of great importance to clarify the molecular mechanism underlying the oncogenesis and development of EC in order to optimize the therapeutic strategies and to improve the prognosis of EC patients. In our present study, we focused on the clinical implications of Nectin-4 expression in human EC tissues and further revealed its potential regulatory role in EC cells. Our results demonstrated that Nectin-4 expression was significantly higher in cancer tissues compared with the adjacent normal tissues, and such up-regulation in cancer tissues was significantly correlated with advanced tumor stage and poorer prognosis of the EC patients. Moreover, our cellular study and in vivo study also showed that the intervention of Nectin-4 in human EC cells could regulate the tumor growth and cellular functions, such as viability, migration ability, invasive ability and cell cycle, suggesting that abnormal expression of Nectin-4 was involved in the cancer progression in this malignancy.

Several clinical investigations have revealed that Nectin-4 can serve as a tumor biomarker, and its...
over-expression in cancer tissues is significantly associated with cancer progression and poorer prognosis of the patients [9, 11–13, 20, 23–25]. It has been demonstrated that higher Nectin-4 expression is found in human gastric cancer tissues compared with the normal gastric tissues, and the expression level of Nectin-4 is significantly associated with cancer cell differentiation, lymph node metastasis, advanced TNM stage and poorer prognosis of the patients [13]. The abnormal expressions of both membranous and soluble forms of Nectin-4 have been found in human breast cancer tissues and sera from the patients. Furthermore, the levels of both two forms of Nectin-4 can be used as important biomarkers and prognostic predictors for breast cancer patients [11, 23, 24]. In human pancreatic carcinoma, the over-expression of Nectin-4 significantly promotes the proliferation of cancer cells and contributes to the intra-tumoral angiogenesis, and it can also be used as an important prognostic predictor for the patients [9]. The underlying molecular mechanism of abnormal Nectin-4 expression in cancer progression still remains to be further investigated. Of note, it has been revealed that over-expression of Nectin-4 in cancer progression can promote the intra-tumoral angiogenesis and facilitate the tumor growth [15, 23]. In addition, the PI3K/AKT signaling pathway is involved in the Nectin-4-mediated promotion of cancer cell proliferation [25–27]. Our present data also showed that increased Nectin-4 expression could significantly enhance the cell proliferation in vitro and tumor growth in vivo. However, the detailed mechanism of Nectin-4 in promoting cancer progression still deserved further investigation.

Collectively, our present findings suggested that over-expression of Nectin-4 promoted the EC progression, and such up-regulation was correlated with the poor prognosis of the patients, and Nectin-4 could serve as a
useful prognostic predictor and an important therapeutic target against EC.

Conclusions

Our present data unveiled that Nectin-4 played an important role in tumor biology and could serve as a useful prognostic predictor of human EC.

Abbreviations

EC: esophageal cancer; IHC: immunohistochemistry; H&E: hematoxylin and eosin; FBS: fetal bovine serum; DMEM: Dulbecco’s modified Eagle’s medium; PBS: phosphate-buffered saline; shRNA: small hairpin RNA.

Authors’ contributions

HD, LC and JJ designed research; HD, HS and YZ performed research; YZ performed the statistical analysis; HD, LC and JJ drafted the manuscript. All authors read and approved the final manuscript.

Author details

1 Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China. 2 Research Center for Cancer Immunotherapy of Jiangsu Province, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China. 3 Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests that would affect this paper.

Availability of data and materials

The authors declare that the data supporting the findings of this study are available within the article.

Consent for publication

Informed consent was provided by each participant in the study.

Ethics approval and consent to participate

The study was carried out under the approval of the ethics committee of the Third Affiliated Hospital of Soochow University.

Funding

This work was supported by grants from the National Key R&D Program (2018YFC1313400), National Natural Science Foundation of Overseas Scholars Cooperation Research Project (31729001), National Natural Science Foundation of China (31570887, 31570908), the Key R&D Project of Science and Technology Department of Jiangsu Province (BE2015633 and BE2018645) and the Changzhou High-Level Medical Talents Training Project (No. 2016CZBJ001).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 February 2019 Accepted: 9 April 2019 Published online: 23 April 2019

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Tortora LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu QX, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

3. Chen L, Luo G, Tan Y, Wei J, Wu C, Zheng L, Zhang X, Xu N. Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem. 2010;112(3):233–9.

4. Boumahdi S, Diessens G, Lapouge G, Rorive S, Nasser D, Le Mercier M, Delatte B, Cauwe A, Lenguez S, Nikusi E, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511(7508):246–50.

5. Chothia C, Jones EY. The molecular structure of cell adhesion molecules. Annu Rev Biochem. 1997;66:823–62.

6. Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci CMLS. 2015;72(4):645–58.

7. Reymond F, Fabre S, Lecoq E, Adelade J, Dubreuil P, Lopez M. Nectin4/PRRM, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem. 2001;276(46):43205–15.

8. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al. Identification of nectin-4 oncprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69(16):6694–703.

9. Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res CR. 2015;34:30.

10. Pavlova NN, Pallach C, Elia AE, Braun CJ, Westbrook TF, Hennemann M, Elledge SJ. A role for PVR4-driven cell–cell interactions in tumorigenesis. eLife. 2013;2:e00358.

11. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R, Adelade J, Geneix J, et al. Nectin-4 is a new histological and serological tumour associated marker for breast cancer. BMC Cancer. 2007;7:73.

12. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol. 2010;134(5):835–45.

13. Zhang Y, Zhang J, Shen Q, Yin W, Huang H, Liu Y, Ni Q. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 2018;15(6):8789–95.

14. Chen L, Feng J, Wu S, Xu B, Zhou Y, Wu C, Jiang J. Decreased RIG-I expression is associated with poor prognosis and promotes cell invasion in human gastric cancer. Cancer Cell Int. 2018;18:144.

15. Chen L, Zhai W, Zheng X, Xie Q, Zhou Q, Tao M, Zhu Y, Wu C, Jiang J. Decreased IFIT2 expression promotes gastric cancer progression and predicts poor prognosis of the patients. Cell Physiol Biochem. 2018;45(1):15–25.

16. Chen L, Zhai W, Zheng X, Xie Q, Zhou Q, Tao M, Zhu Y, Wu C, Jiang J. Decreased Nectin-4 is associated with unfavorable prognosis in gastric cancer. Anticancer Res. 2014;34(10):4363–8.

17. Chen L, Sun J, Wu H, Zhou S, Tan Y, Tan M, Shan B, Lu B, Zhang X. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):233–9.

18. Chen L, Xiong Y, Li J, Zheng X, Zhou Q, Turner A, Wu C, Lu B, Jiang P. Decreased expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 2017;42(6):2267–80.

19. Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q, Shi L, Wu C, Jiang J, Wang H. Knockdown of PD-L1 in human gastric cancer cells inhibits tumor progression and improves the cytotoxic sensitivity to CK therapy. Cell Physiol Biochem. 2017;41(3):907–20.

20. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–509.

21. Chang S, Kohrt H, Maecker HT. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother CII. 2014;63(7):713–9.

22. Chen XG, Chen HZ, Zhu J, Yang YL, Zhang YH, Huang PX, Chen YS, Zhu CY, Yang LP, Shen K, et al. Cancer survival in patients from a hospital-based cancer registry, China. J Cancer. 2018;9(5):851–60.
23. Siddharth S, Nayak A, Das S, Nayak D, Panda J, Wyatt MD, Kundu CN. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial integrin-beta4. Int J Biochem Cell Biol. 2018;102:151–60.

24. Rajc J, Gugic D, Frohlich I, Marjanovic K, Dumencic B. Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer. Pathol Res Pract. 2017;213(9):1102–8.

25. Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z, Lu W, Wang XA, Zhang F, Cao Y, et al. A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 2016;375(1):179–89.

26. Zhang Y, Chen P, Yin W, Ji Y, Shen Q, Ni Q. Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Hum Pathol. 2018;72:107–16.

27. Siddharth S, Goutam K, Das S, Nayak A, Nayak D, Sethy C, Wyatt MD, Kundu CN. Nectin-4 is a breast cancer stem cell marker that induces WNT/beta-catenin signaling via PI3K/Akt axis. Int J Biochem Cell Biol. 2017;89:85–94.